Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Inclusion Criteria

• •Waldenstrom's Macroglobulinemia requiring therapy who have received no more than 2 prior courses of therapy; previously untreated patients with slowly progressive WM if the patient can reasonably be expected to not require chemotherapy or steroid therapy for 90 days
• •CD20 positive tumor cells
• •Presence of monoclonal paraprotein
• •Minimum IgM level \> 2 times the upper limit of normal
• •Adequate organ function: ANC\>1000/uL; PLT \> 25000/uL; serum creatinine \< 2.5; serum total bilirubin and SGOT \< 2.5 times the upper limit of normal
• •18 years and older
• •Life expectancy of 6 months or greater
• •ECOG performance status of 0-2
• •Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for 6 months after completion of treatment